In phase I and II clinical trials, anti-CD47 antibody or SIRPαFc treatment has shown safety, tolerability, and efficacy in advanced colorectal cancer, non-Hodgkin’s lymphoma for cancer immunotherapy (Feng et al., 2019). Here, CD47 is linked to cancer.